Home Healthcare IT Artificial Lung Market

Artificial Lung Market Size, Share & Trends Analysis Report By Product Type (Extracorporeal Membrane Oxygenation (ECMO) Systems, Paracorporeal Artificial Lungs, Intracorporeal Artificial Lungs, Membrane Oxygenators, Portable Artificial Lungs), By Application (Bridge-to-Transplantation, Bridge-to-Recovery, ECMO-assisted Ventilation, Pulmonary Rehabilitation, Long-term Support for Chronic Lung Diseases), By Distribution Channel (Hospital-based Procurement, Direct Tenders and Contracts, Group Purchasing Organizations (GPOs), Online Procurement Platforms (limited role), Third-party Distributors (emerging in select regions)), By End-User (Tertiary Care Hospitals, Transplant Centers, Cardiac and Pulmonary ICUs, Research Institutions and Clinical Trial Sites, Specialty Respiratory Clinics) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: June 03, 2026 | Author: Debashree B | Format: | Report Code: SRHI57463DR | Pages: 155

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Artificial Lung Market Introduction
    2. By Product Type
      1. Introduction
        1. Product Type By Value
      2. Extracorporeal Membrane Oxygenation (ECMO) Systems
        1. By Value
      3. Paracorporeal Artificial Lungs
        1. By Value
      4. Intracorporeal Artificial Lungs
        1. By Value
      5. Membrane Oxygenators
        1. By Value
      6. Portable Artificial Lungs
        1. By Value
    3. By Application
      1. Introduction
        1. Application By Value
      2. Bridge-to-Transplantation
        1. By Value
      3. Bridge-to-Recovery
        1. By Value
      4. ECMO-assisted Ventilation
        1. By Value
      5. Pulmonary Rehabilitation
        1. By Value
      6. Long-term Support for Chronic Lung Diseases
        1. By Value
    4. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Hospital-based Procurement
        1. By Value
      3. Direct Tenders and Contracts
        1. By Value
      4. Group Purchasing Organizations (GPOs)
        1. By Value
      5. Online Procurement Platforms (limited role)
        1. By Value
      6. Third-party Distributors (emerging in select regions)
        1. By Value
    5. By End-User
      1. Introduction
        1. End-User By Value
      2. Tertiary Care Hospitals
        1. By Value
      3. Transplant Centers
        1. By Value
      4. Cardiac and Pulmonary ICUs
        1. By Value
      5. Research Institutions and Clinical Trial Sites
        1. By Value
      6. Specialty Respiratory Clinics
        1. By Value
    1. Introduction
    2. By Product Type
      1. Introduction
        1. Product Type By Value
      2. Extracorporeal Membrane Oxygenation (ECMO) Systems
        1. By Value
      3. Paracorporeal Artificial Lungs
        1. By Value
      4. Intracorporeal Artificial Lungs
        1. By Value
      5. Membrane Oxygenators
        1. By Value
      6. Portable Artificial Lungs
        1. By Value
    3. By Application
      1. Introduction
        1. Application By Value
      2. Bridge-to-Transplantation
        1. By Value
      3. Bridge-to-Recovery
        1. By Value
      4. ECMO-assisted Ventilation
        1. By Value
      5. Pulmonary Rehabilitation
        1. By Value
      6. Long-term Support for Chronic Lung Diseases
        1. By Value
    4. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Hospital-based Procurement
        1. By Value
      3. Direct Tenders and Contracts
        1. By Value
      4. Group Purchasing Organizations (GPOs)
        1. By Value
      5. Online Procurement Platforms (limited role)
        1. By Value
      6. Third-party Distributors (emerging in select regions)
        1. By Value
    5. By End-User
      1. Introduction
        1. End-User By Value
      2. Tertiary Care Hospitals
        1. By Value
      3. Transplant Centers
        1. By Value
      4. Cardiac and Pulmonary ICUs
        1. By Value
      5. Research Institutions and Clinical Trial Sites
        1. By Value
      6. Specialty Respiratory Clinics
        1. By Value
    6. U.S.
      1. By Product Type
        1. Introduction
          1. Product Type By Value
        2. Extracorporeal Membrane Oxygenation (ECMO) Systems
          1. By Value
        3. Paracorporeal Artificial Lungs
          1. By Value
        4. Intracorporeal Artificial Lungs
          1. By Value
        5. Membrane Oxygenators
          1. By Value
        6. Portable Artificial Lungs
          1. By Value
      2. By Application
        1. Introduction
          1. Application By Value
        2. Bridge-to-Transplantation
          1. By Value
        3. Bridge-to-Recovery
          1. By Value
        4. ECMO-assisted Ventilation
          1. By Value
        5. Pulmonary Rehabilitation
          1. By Value
        6. Long-term Support for Chronic Lung Diseases
          1. By Value
      3. By Distribution Channel
        1. Introduction
          1. Distribution Channel By Value
        2. Hospital-based Procurement
          1. By Value
        3. Direct Tenders and Contracts
          1. By Value
        4. Group Purchasing Organizations (GPOs)
          1. By Value
        5. Online Procurement Platforms (limited role)
          1. By Value
        6. Third-party Distributors (emerging in select regions)
          1. By Value
      4. By End-User
        1. Introduction
          1. End-User By Value
        2. Tertiary Care Hospitals
          1. By Value
        3. Transplant Centers
          1. By Value
        4. Cardiac and Pulmonary ICUs
          1. By Value
        5. Research Institutions and Clinical Trial Sites
          1. By Value
        6. Specialty Respiratory Clinics
          1. By Value
    7. Canada
    1. Introduction
    2. By Product Type
      1. Introduction
        1. Product Type By Value
      2. Extracorporeal Membrane Oxygenation (ECMO) Systems
        1. By Value
      3. Paracorporeal Artificial Lungs
        1. By Value
      4. Intracorporeal Artificial Lungs
        1. By Value
      5. Membrane Oxygenators
        1. By Value
      6. Portable Artificial Lungs
        1. By Value
    3. By Application
      1. Introduction
        1. Application By Value
      2. Bridge-to-Transplantation
        1. By Value
      3. Bridge-to-Recovery
        1. By Value
      4. ECMO-assisted Ventilation
        1. By Value
      5. Pulmonary Rehabilitation
        1. By Value
      6. Long-term Support for Chronic Lung Diseases
        1. By Value
    4. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Hospital-based Procurement
        1. By Value
      3. Direct Tenders and Contracts
        1. By Value
      4. Group Purchasing Organizations (GPOs)
        1. By Value
      5. Online Procurement Platforms (limited role)
        1. By Value
      6. Third-party Distributors (emerging in select regions)
        1. By Value
    5. By End-User
      1. Introduction
        1. End-User By Value
      2. Tertiary Care Hospitals
        1. By Value
      3. Transplant Centers
        1. By Value
      4. Cardiac and Pulmonary ICUs
        1. By Value
      5. Research Institutions and Clinical Trial Sites
        1. By Value
      6. Specialty Respiratory Clinics
        1. By Value
    6. U.K.
      1. By Product Type
        1. Introduction
          1. Product Type By Value
        2. Extracorporeal Membrane Oxygenation (ECMO) Systems
          1. By Value
        3. Paracorporeal Artificial Lungs
          1. By Value
        4. Intracorporeal Artificial Lungs
          1. By Value
        5. Membrane Oxygenators
          1. By Value
        6. Portable Artificial Lungs
          1. By Value
      2. By Application
        1. Introduction
          1. Application By Value
        2. Bridge-to-Transplantation
          1. By Value
        3. Bridge-to-Recovery
          1. By Value
        4. ECMO-assisted Ventilation
          1. By Value
        5. Pulmonary Rehabilitation
          1. By Value
        6. Long-term Support for Chronic Lung Diseases
          1. By Value
      3. By Distribution Channel
        1. Introduction
          1. Distribution Channel By Value
        2. Hospital-based Procurement
          1. By Value
        3. Direct Tenders and Contracts
          1. By Value
        4. Group Purchasing Organizations (GPOs)
          1. By Value
        5. Online Procurement Platforms (limited role)
          1. By Value
        6. Third-party Distributors (emerging in select regions)
          1. By Value
      4. By End-User
        1. Introduction
          1. End-User By Value
        2. Tertiary Care Hospitals
          1. By Value
        3. Transplant Centers
          1. By Value
        4. Cardiac and Pulmonary ICUs
          1. By Value
        5. Research Institutions and Clinical Trial Sites
          1. By Value
        6. Specialty Respiratory Clinics
          1. By Value
    7. Germany
    8. France
    9. Spain
    10. Italy
    11. Russia
    12. Nordic
    13. Benelux
    14. Rest of Europe
    1. Introduction
    2. By Product Type
      1. Introduction
        1. Product Type By Value
      2. Extracorporeal Membrane Oxygenation (ECMO) Systems
        1. By Value
      3. Paracorporeal Artificial Lungs
        1. By Value
      4. Intracorporeal Artificial Lungs
        1. By Value
      5. Membrane Oxygenators
        1. By Value
      6. Portable Artificial Lungs
        1. By Value
    3. By Application
      1. Introduction
        1. Application By Value
      2. Bridge-to-Transplantation
        1. By Value
      3. Bridge-to-Recovery
        1. By Value
      4. ECMO-assisted Ventilation
        1. By Value
      5. Pulmonary Rehabilitation
        1. By Value
      6. Long-term Support for Chronic Lung Diseases
        1. By Value
    4. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Hospital-based Procurement
        1. By Value
      3. Direct Tenders and Contracts
        1. By Value
      4. Group Purchasing Organizations (GPOs)
        1. By Value
      5. Online Procurement Platforms (limited role)
        1. By Value
      6. Third-party Distributors (emerging in select regions)
        1. By Value
    5. By End-User
      1. Introduction
        1. End-User By Value
      2. Tertiary Care Hospitals
        1. By Value
      3. Transplant Centers
        1. By Value
      4. Cardiac and Pulmonary ICUs
        1. By Value
      5. Research Institutions and Clinical Trial Sites
        1. By Value
      6. Specialty Respiratory Clinics
        1. By Value
    6. China
      1. By Product Type
        1. Introduction
          1. Product Type By Value
        2. Extracorporeal Membrane Oxygenation (ECMO) Systems
          1. By Value
        3. Paracorporeal Artificial Lungs
          1. By Value
        4. Intracorporeal Artificial Lungs
          1. By Value
        5. Membrane Oxygenators
          1. By Value
        6. Portable Artificial Lungs
          1. By Value
      2. By Application
        1. Introduction
          1. Application By Value
        2. Bridge-to-Transplantation
          1. By Value
        3. Bridge-to-Recovery
          1. By Value
        4. ECMO-assisted Ventilation
          1. By Value
        5. Pulmonary Rehabilitation
          1. By Value
        6. Long-term Support for Chronic Lung Diseases
          1. By Value
      3. By Distribution Channel
        1. Introduction
          1. Distribution Channel By Value
        2. Hospital-based Procurement
          1. By Value
        3. Direct Tenders and Contracts
          1. By Value
        4. Group Purchasing Organizations (GPOs)
          1. By Value
        5. Online Procurement Platforms (limited role)
          1. By Value
        6. Third-party Distributors (emerging in select regions)
          1. By Value
      4. By End-User
        1. Introduction
          1. End-User By Value
        2. Tertiary Care Hospitals
          1. By Value
        3. Transplant Centers
          1. By Value
        4. Cardiac and Pulmonary ICUs
          1. By Value
        5. Research Institutions and Clinical Trial Sites
          1. By Value
        6. Specialty Respiratory Clinics
          1. By Value
    7. Korea
    8. Japan
    9. India
    10. Australia
    11. Taiwan
    12. South East Asia
    13. Rest of Asia-Pacific
    1. Introduction
    2. By Product Type
      1. Introduction
        1. Product Type By Value
      2. Extracorporeal Membrane Oxygenation (ECMO) Systems
        1. By Value
      3. Paracorporeal Artificial Lungs
        1. By Value
      4. Intracorporeal Artificial Lungs
        1. By Value
      5. Membrane Oxygenators
        1. By Value
      6. Portable Artificial Lungs
        1. By Value
    3. By Application
      1. Introduction
        1. Application By Value
      2. Bridge-to-Transplantation
        1. By Value
      3. Bridge-to-Recovery
        1. By Value
      4. ECMO-assisted Ventilation
        1. By Value
      5. Pulmonary Rehabilitation
        1. By Value
      6. Long-term Support for Chronic Lung Diseases
        1. By Value
    4. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Hospital-based Procurement
        1. By Value
      3. Direct Tenders and Contracts
        1. By Value
      4. Group Purchasing Organizations (GPOs)
        1. By Value
      5. Online Procurement Platforms (limited role)
        1. By Value
      6. Third-party Distributors (emerging in select regions)
        1. By Value
    5. By End-User
      1. Introduction
        1. End-User By Value
      2. Tertiary Care Hospitals
        1. By Value
      3. Transplant Centers
        1. By Value
      4. Cardiac and Pulmonary ICUs
        1. By Value
      5. Research Institutions and Clinical Trial Sites
        1. By Value
      6. Specialty Respiratory Clinics
        1. By Value
    6. UAE
      1. By Product Type
        1. Introduction
          1. Product Type By Value
        2. Extracorporeal Membrane Oxygenation (ECMO) Systems
          1. By Value
        3. Paracorporeal Artificial Lungs
          1. By Value
        4. Intracorporeal Artificial Lungs
          1. By Value
        5. Membrane Oxygenators
          1. By Value
        6. Portable Artificial Lungs
          1. By Value
      2. By Application
        1. Introduction
          1. Application By Value
        2. Bridge-to-Transplantation
          1. By Value
        3. Bridge-to-Recovery
          1. By Value
        4. ECMO-assisted Ventilation
          1. By Value
        5. Pulmonary Rehabilitation
          1. By Value
        6. Long-term Support for Chronic Lung Diseases
          1. By Value
      3. By Distribution Channel
        1. Introduction
          1. Distribution Channel By Value
        2. Hospital-based Procurement
          1. By Value
        3. Direct Tenders and Contracts
          1. By Value
        4. Group Purchasing Organizations (GPOs)
          1. By Value
        5. Online Procurement Platforms (limited role)
          1. By Value
        6. Third-party Distributors (emerging in select regions)
          1. By Value
      4. By End-User
        1. Introduction
          1. End-User By Value
        2. Tertiary Care Hospitals
          1. By Value
        3. Transplant Centers
          1. By Value
        4. Cardiac and Pulmonary ICUs
          1. By Value
        5. Research Institutions and Clinical Trial Sites
          1. By Value
        6. Specialty Respiratory Clinics
          1. By Value
    7. Turkey
    8. Saudi Arabia
    9. South Africa
    10. Egypt
    11. Nigeria
    12. Rest of MEA
    1. Introduction
    2. By Product Type
      1. Introduction
        1. Product Type By Value
      2. Extracorporeal Membrane Oxygenation (ECMO) Systems
        1. By Value
      3. Paracorporeal Artificial Lungs
        1. By Value
      4. Intracorporeal Artificial Lungs
        1. By Value
      5. Membrane Oxygenators
        1. By Value
      6. Portable Artificial Lungs
        1. By Value
    3. By Application
      1. Introduction
        1. Application By Value
      2. Bridge-to-Transplantation
        1. By Value
      3. Bridge-to-Recovery
        1. By Value
      4. ECMO-assisted Ventilation
        1. By Value
      5. Pulmonary Rehabilitation
        1. By Value
      6. Long-term Support for Chronic Lung Diseases
        1. By Value
    4. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Hospital-based Procurement
        1. By Value
      3. Direct Tenders and Contracts
        1. By Value
      4. Group Purchasing Organizations (GPOs)
        1. By Value
      5. Online Procurement Platforms (limited role)
        1. By Value
      6. Third-party Distributors (emerging in select regions)
        1. By Value
    5. By End-User
      1. Introduction
        1. End-User By Value
      2. Tertiary Care Hospitals
        1. By Value
      3. Transplant Centers
        1. By Value
      4. Cardiac and Pulmonary ICUs
        1. By Value
      5. Research Institutions and Clinical Trial Sites
        1. By Value
      6. Specialty Respiratory Clinics
        1. By Value
    6. Brazil
      1. By Product Type
        1. Introduction
          1. Product Type By Value
        2. Extracorporeal Membrane Oxygenation (ECMO) Systems
          1. By Value
        3. Paracorporeal Artificial Lungs
          1. By Value
        4. Intracorporeal Artificial Lungs
          1. By Value
        5. Membrane Oxygenators
          1. By Value
        6. Portable Artificial Lungs
          1. By Value
      2. By Application
        1. Introduction
          1. Application By Value
        2. Bridge-to-Transplantation
          1. By Value
        3. Bridge-to-Recovery
          1. By Value
        4. ECMO-assisted Ventilation
          1. By Value
        5. Pulmonary Rehabilitation
          1. By Value
        6. Long-term Support for Chronic Lung Diseases
          1. By Value
      3. By Distribution Channel
        1. Introduction
          1. Distribution Channel By Value
        2. Hospital-based Procurement
          1. By Value
        3. Direct Tenders and Contracts
          1. By Value
        4. Group Purchasing Organizations (GPOs)
          1. By Value
        5. Online Procurement Platforms (limited role)
          1. By Value
        6. Third-party Distributors (emerging in select regions)
          1. By Value
      4. By End-User
        1. Introduction
          1. End-User By Value
        2. Tertiary Care Hospitals
          1. By Value
        3. Transplant Centers
          1. By Value
        4. Cardiac and Pulmonary ICUs
          1. By Value
        5. Research Institutions and Clinical Trial Sites
          1. By Value
        6. Specialty Respiratory Clinics
          1. By Value
    7. Mexico
    8. Argentina
    9. Chile
    10. Colombia
    11. Rest of LATAM
    1. Artificial Lung Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Getinge AB
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Xenios AG (Fresenius Medical Care)
    3. Medtronic plc
    4. Abbott Laboratories
    5. Abiomed (Johnson and Johnson MedTech)
    6. LivaNova PLC
    7. MicroPort Scientific Corporation
    8. ALung Technologies, Inc.
    9. Novalung GmbH (a Xenios company)
    10. Nipro Corporation
    11. Hemovent GmbH
    12. Braile Biomédica
    13. MC3 Cardiopulmonary
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer
Get This Report

Download Free Sample

Our Clients:

LG Electronics
AMCAD Engineering
KOBE STEEL LTD.
Hindustan National Glass & Industries Limited
Voith Group
International Paper
Hansol Paper
Whirlpool Corporation
Sony
Samsung Electronics
Qualcomm
Google
Fiserv
Veto-Pharma
Nippon Becton Dickinson
Merck
Argon Medical Devices
Abbott
Ajinomoto
Denon
Doosan
Meiji Seika Kaisha Ltd
LG Chemicals
LCY chemical group
Bayer
Airrane
BASF
Toyota Industries
Nissan Motors
Neenah
Mitsubishi
Hyundai Motor Company

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.